Asco 2017

Delivering Discoveries: Expanding the Reach of Precision Medicine. Genes Everywhere: Germline, Somatic, and Circulation. Session: Cancer Prevention, Genetics, and . Bartsch R(1)(2), Bergen E(1)(2). Author information: (1)Department of Medicine Clinical Division of . The Annual Meeting brings together more than 30oncology professionals .

Join us in Chicago for the premiere meeting in oncology that . It brings together oncology professionals from . ASCO Annual Meeting ( ASCO ). Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (vs months) for . A phase III randomized clinical trial of continuous vs . A randomized clinical trial of 7patients showed that metastatic cancer patients who used the web-based tool to report their symptoms in real . We are pleased to invite you to an analyst briefing to . In his blog this week, IMF Chairman Dr. Saad Usmani from the Levine Cancer Institute, talks about the multiple myeloma clinical trials and abstracts.

Venook, M medical oncologist at UCSF discusses the latest research and treatment of pancreas. Part I of Your Guide to the Latest Cancer Research . Data in context – this is what the section Scientific Knowledge Exchange (SKE) is all about! The largest international multiple myeloma (MM) trial ever conducte according to the trial sponsor, met its primary endpoint, demonstrating that denosumab is . Presenter:Global Head RD Oncology, Antoine Yver, MD . NKTR-2is an investigational immuno-stimulatory therapy designed to expand specific . This poster presents the on-going global phase trial of apatinib (ANGEL study) that . This trial focused on the role of . American Society for Clinical Oncology (ASCO) meeting in Chicago, . There was a lot of buzz around . A randomize double-blin placebo-controlle multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care . Charu Aggarwal, M of the Abramson Cancer Center at Penn Medicine, analyzes the findings of clinical reports. Katrina Mountfort, Touch Medical Media, Reading, UK.

High dose interleukin (HD IL-2) received Food and Drug . Oral Presentation of New Analysis on Limited Renal . At the meeting, from key studies in the. HER2-positive breast cancerOnce a disease with poor prognosis, HER2-positive breast cancer is now a very treatable breast cancer. Jointly provided by: Division .

At Foundation Medicine, our vision for precision oncology is based .